Shares of drugmaker Bristol-Myers Squibb have rocketed upward since the start of 2013, trouncing the S&P 500 and many of its big pharma peers after reporting positive clinical trial data earlier this year. That doesn't mean, however, that Bristol no longer has room to grow. In the following video, taken from The Motley Fool's health care show, health care analysts David Williamson and Max Macaluso examine Bristol's biggest opportunities and some of the competitors it is currently facing.
One of the best parts of owning big pharma stocks like Bristol-Myers Squibb is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Opportunities Bristol-Myers Squibb Investors Need to Watch originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.